Asia-Pacific In-Vitro diagnostics market has been estimated at USD 13.31 billion in 2018 and is poised to reach 18.15 billion at a Compound Annual Growth Rate (CAGR) of 6.4%. In-Vitro diagnostics can be described as tests that can help in detecting diseases, conditions or infections. Some of these tests are performed in laboratory or healthcare settings while other tests are for consumers to use at home.
In-Vitro diagnostics test a sample of tissue or body fluids for microbial cultures or blood glucose. They are also used for testing changes in the liver function, imbalance in calcium levels in the body and electrolytes in the blood such as sodium, urea, potassium and Creatinine. The end users of In Vitro diagnostics market are generally Laboratories, Hospitals, Academic institutions, Point-of-care testing centers. There are around 40,000 IVD products available in the market assisting patients and specialists on a wide range of conditions
In-Vitro Diagnostics market is expected to witness faster growth owing to advancements and innovations in the IVD technologies. Rising geriatric population base, growing prevalence of diabetes are the key factors driving the growth of the market. Increasing recognition of the diabetic’s role in the patient care and rapidly evolving healthcare environment due to growing awareness about various diseases are expected to drive the In-Vitro market in the forecast period. However stringent regulatory policies and unclear reimbursement policies are restraining the growth of the market.
In-Vitro Diagnostics is segmented on the basis of product, technology and by application. On the basis of product the market is again sub segmented into instruments, reagents and kits, Data management system/software and services. On the basis of technology the in-vitro diagnostics market is sub segmented into Clinical Chemistry, Hematology, immunoassays, Coagulation and Hemostasis, molecular diagnostics, microbiology and other IVD technologies. On the basis of application the market for In-Vitro diagnostics is segmented into Diabetes, Infectious Diseases, Oncology/Cancer, Cardiology, Nephrology, Autoimmune Diseases, Drug testing and HIV
On the basis of geography Asia-Pacific market for In-Vitro diagnostics is segmented into China, India, Japan and others. China Is the largest market for In-Vitro diagnostics accounting for a share of around XX% owing to growing prevalence of chronic diseases such as cancer and respiratory diseases in the region while India is estimated to be the fastest growing segment with a CAGR of XX%.
Abbott Laboratories, Johnson and Johnson, Siemens Healthcare, Becton Dickinson, Roche Diagnostics, and Beckman Coulter Inc. are the major players dominating the global IVD market. Other companies which account for a significant share in the IVD market are Biomérieux, Ortho Clinical Diagnostics, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Sysmex Corporation and Thermo Fisher Scientific, Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Product
5.1.1 Instruments
5.1.2 Reagents and Kits
5.1.3 Software
5.2 By Technology
5.2.1 Clinical Chemistry
5.2.2 Hematology
5.2.3 Immunoassays
5.2.4 Coagulation and Hemostasis
5.2.5 Molecular Diagnostics
5.2.6 Microbiology
5.2.7 Other IVD technologies
5.3 By Application
5.3.1 Diabetes
5.3.2 Infectious Diseases
5.3.3 Oncology/Cancer
5.3.4 Cardiology
5.3.5 Nephrology
5.3.6 Autoimmune Diseases
5.3.7 Drug Testing
5.3.8 HIV
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Johnson and Johnson
8.3 Siemens Healthcare
8.4 Becton Dickinson
8.5 Roche Diagnostics
8.6 Beckman Coulter Inc.
8.7 Biomérieux
8.8 Ortho Clinical Diagnostics, Inc.
8.9 Bio-Rad Laboratories, Inc.
8.10 Danaher Corporation
8.11 Sysmex Corporation
8.12 Thermo Fisher Scientific, Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
